Phase II trial of sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC)

被引：0
|
作者：
Cupini, S. [1 ]
Bursi, S. [1 ]
Masi, G. [1 ]
Loupakis, F. [1 ]
Barbara, C. [1 ]
Fornaro, L. [1 ]
Allegrini, G. [1 ]
Di Marsico, R. [1 ]
Andreuccetti, M. [1 ]
Falcone, A. [2 ]
机构：
[1] Az USL 6, Div Med Oncol, Livorno, Italy
[2] Univ Pisa, Dept Oncol, Pisa, Italy
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)70979-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3051
引用
收藏
页码：251 / 251
页数：1
相关论文
共 50 条
  • [1] Sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC)
    Cupini, S.
    Bursi, S.
    Masi, G.
    Loupakis, F.
    Barbara, C.
    Barletta, M. T.
    Baldi, G. G.
    Vasile, E.
    Fornaro, L.
    Petrini, I.
    Allegrini, G.
    Antonuzzo, A.
    Di Marsico, R.
    Andreuccetti, M.
    Ricci, S.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : 6 - 6
  • [2] OXALIPLATIN AND CAPECITABINE (XELOX) PLUS BEVACIZUMAB (BEVA) FOR ELDERLY PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (mCRC): BOXE, A PHASE II TRIAL
    Rosati, Gerardo
    Cordio, Stefano
    Leo, Silvana
    Daniele, Bruno
    Butera, Alfredo
    [J]. ANNALS OF ONCOLOGY, 2011, 22 : v104 - v104
  • [3] Phase II study of capecitabine plus oxaliplatin (XELOX) followed by capecitabine plus irinotecan (XELIRI) in a sequential schedule in first-line metastatic colorectal cancer (MCRC)
    Cassinello, Javier
    Alvarez, Jose V.
    Garcia Lopez, Maria J.
    Pujol, Eduardo
    Colmenarejo, Antonio
    De Segovia, Fernando
    Marcos, Fernando
    Filipovich, Elena
    Arcediano, Alberto
    Garcia Castro, Ines
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 116 - 117
  • [4] A phase II trial of capecitabine (X) and irinotecan (I), in a biweekly schedule, for patients (Pts) with advanced/metastatic colorectal cancer (MCRC).
    Garcia-Alfonso, P
    Gonzalez-Arenas, C
    Gonzalez-Flores, E
    Molina, M
    Muñoz, A
    Abad, G
    Garcia-Adrian, S
    Lopez, P
    Belon, J
    Perez-Manga, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 290S - 290S
  • [5] EFFICACY AND SAFETY OF CAPECITABINE AND IRINOTECAN (CAPIRI) IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Bounedjar, Adda
    Smaili, Farida
    [J]. ANNALS OF ONCOLOGY, 2011, 22 : v99 - v99
  • [6] PHASE II: SEQUENTIAL SCHEME CAPECITABINE-OXALIPLATIN FOLLOWED BY CAPECITABINE-IRINOTECAN (OXXEC-02) IN FIRST LINE METASTATIC COLORECTAL CANCER (MCRC). STUDY OXXEC-02
    De Toro, R.
    Lobo, M.
    Albero, A.
    De la Cruz, L.
    Murillo, E.
    Virizuela, J.
    Portillo, M.
    Barros, M.
    Casinello, J.
    Codes, M.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 128 - 128
  • [7] Phase II multicenter study of capecitabine plus oxaliplatin (XELOX) sequentially followed by capecitabine and irinotecan (XELIRI) in first-line therapy for metastatic colorectal cancer (MCRC)
    Cassinello, J.
    Alvarez, J. V.
    Garcia-Lopez, M. J.
    Pujol, E.
    Colmenarejo, A.
    De Segovia, F.
    Marcos, F.
    Filipovich, E.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 199 - 200
  • [8] A PHASE II STUDY OF CAPECITABINE, IRINOTECAN, AND BEVACIZUMAB (XELIRI-A) IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (MCRC)
    Chen, E.
    Welch, S.
    Kryzanowska, M.
    Mackay, H.
    Knox, J.
    Feld, R.
    Petronis, J.
    Blatter, C.
    Wang, L.
    Moore, M.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 : 36 - 37
  • [9] A phase II study of capecitabine, irinotecan, and bevacizumab (XELIRI-A) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC)
    Chen, E. X.
    Welch, S.
    Krzyzanowska, M.
    MacKay, H.
    Knox, J.
    Feld, R.
    Petronis, J.
    Blatter, C.
    Wang, L.
    Moore, M. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] CAPECITABINE AND IRINOTECAN (CAPIRI) AS FIRST - LINE TREATMENT FOR PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Adda, B.
    Farida, S.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 : 73 - 73
12345